10-K/A: Envoy Medical Files 10-K Amendment with Certifications

Envoy Medical, Inc. has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct a typographical error in an auditor's consent and to include updated certifications.

Summary

• Envoy Medical, Inc. has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• The primary purpose of this amendment is to correct a typographical error in the consent of Grant Thornton LLP, the company's independent registered public accounting firm.
• The amendment also includes new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, signed by the CEO, Brent T. Lucas, and the Interim CFO, Robert Potashnick.
• These certifications affirm that the report does not contain any untrue statements of material fact or omit necessary material facts.
• No other changes have been made to the original Form 10-K, and it has not been updated for events occurring after its initial filing date, except as specifically set forth in this amendment.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a low score due to the filing being a procedural amendment correcting a minor error and re-issuing certifications, rather than containing new operational or financial information.

Future Outlook

This amendment does not contain any new forward-looking statements or guidance beyond what was in the original Form 10-K.

Management Comments

• Robert Potashnick (Interim Chief Financial Officer) certifies that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
• Brent T. Lucas (Chief Executive Officer) certifies that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Industry Context

StockSavvy.ai notes that this filing is a procedural amendment to a prior annual report, focusing on correcting an administrative detail and re-certifying compliance with financial reporting standards. Such amendments are common and typically do not signal new operational or financial developments.

Corporate Governance

Stakeholder Impact

• Shareholders: The amendment provides assurance regarding the accuracy of the company's financial reporting for the fiscal year ended December 31, 2025, reinforcing confidence in the disclosed information.

Key Dates

Keywords

10-K Amendment, Envoy Medical, SEC Filing, Sarbanes-Oxley Act, Financial Reporting, Corporate Governance, Grant Thornton LLP